Mother and daughter

Pipeline

A Different Kind of Precision Medicine

We are building a pipeline of targeted cancer therapies by harnessing both our macrocycle platform and our expertise in structure-based design.

Our pipeline is built on small molecule, orally available therapies designed to bind to their targets with greater precision and affinity than other kinase inhibitors. By precisely targeting the cell signaling pathways that drive cancer growth and progression, we have selected each drug candidate in our pipeline for its potential to be a best-in-class therapy.

Repotrectinib (ROS1/TRK)1

Discovery
Preclinical
Early Stage Clinical Development
Late Stage Clinical Development
Regulatory Submission

TRIDENT-1: Advanced NSCLC (ROS1) And Solid Tumors (NTRK)

 
 
 
 
 

CARE: Pediatric Advanced Solid Tumors

 
 
 
 
 

TRIDENT-2: KRAS-Targeting Combination

 
 
 
 
 

TPX-0022 (MET)1

SHIELD-1: Advanced Solid Tumors

SHIELD-2: EGFR Combination

TPX-0046 (RET)2

SWORD-1: Advanced Solid Tumors

 
 
 
 
 

TPX-0131 (ALK)2

FORGE-1: Advanced NSCLC

 
 
 
 
 

Discovery Programs

KRAS G12D

 
 
 
 
 

p21 Activated Kinase

 
 
 
 
 

Multiple GTPase Oncology Targets

 
 
 
 
 

1Partnered with Zai Lab in Greater China; Turning Point retains worldwide rights outside of Greater China.

2Turning Point retains worldwide rights.